MNA
RPRX icon

Manning & Napier Advisors’s Royalty Pharma RPRX Stock Holding History

Manning & Napier Advisors’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-36,549
Closed -$1.14M – 339
2025
Q1 		$1.14M Sell
36,549
-44,505
-55% -$1.41M 0.01% 246
2024
Q4 		$2.07M Sell
81,054
-52,510
-39% -$1.39M 0.02% 220
2024
Q3 		$3.78M Sell
133,564
-62,289
-32% -$1.73M 0.04% 210
2024
Q2 		$5.16M Buy
+195,853
New +$5.43M 0.06% 177

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CIA
Caledonia Investments (Australia) Sydney NSW, Australia $3.44B AUM 20.03% 1-Year Est. Return

Manning & Napier Advisors's RPRX Position: Q2 2025 in Review

Manning & Napier Advisors sold out of Royalty Pharma (RPRX) in Q2 2025, closing a stake of 36,549 shares — an estimated $1.14M sold.

Manning & Napier Advisors first reported a position in RPRX in Q2 2024 and held it in 4 quarters. The position peaked at $5.16M in Q2 2024. 455 funds tracked by Wall St. Rank hold RPRX as of Q2 2025.

  • Manning & Napier Advisors reported no remaining Royalty Pharma position as of Q2 2025 after selling out during the quarter.
  • Manning & Napier Advisors sold 36,549 Royalty Pharma shares in Q2 2025, an estimated $1.14M.
  • Manning & Napier Advisors first reported a position in Royalty Pharma in Q2 2024 and held it in 4 quarters.
  • Manning & Napier Advisors's Royalty Pharma position peaked at $5.16M in Q2 2024.
  • 455 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2025.

Based on Manning & Napier Advisors's 13F filing for Q2 2025, filed 13 Aug 2025.